Nektar signs up on record-breaking collaboration deal
Rather surprisingly, US biotech firm Nektar Therapeutics (Nasdaq: NKTR) was trading down 4.32% at $72.39 pre-market this morning, even though news had broken that it has entered into a collaboration which, including an equity investment, could be worth a record-breaking $3.6 billion. However, after the market opened, the stock started moving up around 8% to $81.74 by mid-morning.
Nektar has executed a global strategic development and commercialization collaboration with pharma major Bristol-Myers Squibb (NYSE: BMY) for its lead immuno-oncology program, NKTR-214, as B-MS searches for a competitive edge over Keytruda (pembrolizumab) and other rival checkpoint inhibitors.
Under the collaboration, the companies will jointly develop and commercialize NKTR-214 in combination with B-MS’ Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in more than 20 indications across nine tumor types, as well as potential combinations with other anti-cancer agents from either of the respective companies and/or third parties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze